Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin Receptor Binding in the Hippocampus: Testing the \lquotelcurlybrcurlybTwo Hit\rquotelcurlybrcurlyb Hypothesis for the Development of Schizophrenia
Infections during pregnancy and adolescent cannabis use have both been identified as environmental risk factors for schizophrenia. We combined these factors in an animal model and looked at their effects, alone and in combination, on serotonin 5 H T 1 A receptor binding ( 5 H T 1 A R ) binding longitudinally from late adolescence to adulthood. Pregnant rats were exposed to the viral mimic poly I:C on embryonic day 15. Adolescent offspring received daily injections of the cannabinoid HU210 for 14 days starting on postnatal day (PND) 35. Hippocampal and cortical 5 H T 1 A R binding was quantified autoradiographically using [3H]8-OH-DPAT, in late adolescent (PND 55), young adult (PND 65) and adult (PND 90) rats. Descendants of poly I:C treated rats showed significant increases of 15–18% in 5 H T 1 A R in the hippocampus (CA1) compared to controls at all developmental ages. Offspring of poly I:C treated rats exposed to HU210 during adolescence exhibited even greater elevations in 5 H T 1 A R (with increases of 44, 29, and 39% at PNDs 55, 65, and 90). No effect of HU210 alone was observed. Our results suggest a synergistic effect of prenatal infection and adolescent cannabinoid exposure on the integrity of the serotoninergic system in the hippocampus that may provide the neurochemical substrate for abnormal hippocampal-related functions relevant to schizophrenia. 1. Introduction Schizophrenia is a chronic, severe and disabling brain disease, affecting approximately one percent of the population worldwide [1]. The overt signs and symptoms of schizophrenia do not usually manifest until late adolescence but it is believed that the disorder arises from genetic and/or environmental factors encountered prior to disease onset. Amongst the early insults that increase the risk for schizophrenia, prenatal exposure to viral or bacterial infection has been implicated as a strong risk factor by epidemiological studies [2]. The mechanisms by which brain development is altered in offspring following maternal infection remain unknown but it appears that maternal immune activation and in particular proinflammatory cytokines produced in order to fight the infection, rather the infection per se, is responsible [3–5]. Although late risk factors have been difficult to identify, various lines of evidence suggest an association between cannabis use in adolescence and the onset of schizophrenia symptoms. Cannabis increases the risk for psychotic outcomes in a dose-response manner [6]. However, only a minority of cannabis users develop psychosis suggesting that cannabis may interact
References
[1]
R. Tandon, M. S. Keshavan, and H. A. Nasrallah, “Schizophrenia, "Just the Facts": what we know in 2008. Part 1: Overview,” Schizophrenia Research, vol. 100, no. 1–3, pp. 4–19, 2008.
[2]
P. H. Patterson, “Maternal effects on schizophrenia risk,” Science, vol. 318, no. 5850, pp. 576–577, 2007.
[3]
U. Meyer and J. Feldon, “Epidemiology-driven neurodevelopmental animal models of schizophrenia,” Progress in Neurobiology, vol. 90, no. 3, pp. 285–326, 2010.
[4]
L. Shi, N. Tu, and P. H. Patterson, “Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus,” International Journal of Developmental Neuroscience, vol. 23, no. 2-3, pp. 299–305, 2005.
[5]
C. Winter, A. Djodari-Irani, R. Sohr et al., “Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia,” International Journal of Neuropsychopharmacology, vol. 12, no. 4, pp. 513–524, 2009.
[6]
C. Henquet, L. Krabbendam, J. Spauwen et al., “Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people,” British Medical Journal, vol. 330, no. 7481, pp. 11–14, 2005.
[7]
A. Abi-Dargham, M. Laruelle, G. K. Aghajanian, D. Charney, and J. Krystal, “The role of serotonin in the pathophysiology and treatment of schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 9, no. 1, pp. 1–17, 1997.
[8]
P. W. J. Burnet, S. L. Eastwood, and P. J. Harrison, “5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia,” Neuropsychopharmacology, vol. 15, no. 5, pp. 442–455, 1996.
[9]
J. N. Joyce, A. Shane, N. Lexow, A. Winokur, M. F. Casanova, and J. E. Kleinman, “Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics,” Neuropsychopharmacology, vol. 8, no. 4, pp. 315–336, 1993.
[10]
M. D. C. Simpson, D. I. Lubman, P. Slater, and J. F. W. Deakin, “Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia,” Biological Psychiatry, vol. 39, no. 11, pp. 919–928, 1996.
[11]
Y. Ohno, “Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease,” CNS Neuroscience and Therapeutics, vol. 17, no. 1, pp. 58–65, 2011.
[12]
S. H. Fatemi, T. J. Reutiman, T. D. Folsom et al., “Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders,” Schizophrenia Research, vol. 99, no. 1–3, pp. 56–70, 2008.
[13]
S. Wang, J. Y. Yan, Y. K. Lo, P. M. Carvey, and Z. Ling, “Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide,” Brain Research, vol. 1265, pp. 196–204, 2009.
[14]
B. Abazyan, J. Nomura, G. Kannan et al., “Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology,” Biological Psychiatry, vol. 68, no. 12, pp. 1172–1181, 2010.
[15]
Y. Piontkewitz, M. Arad, and I. Weiner, “Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia,” Schizophrenia Bulletin, vol. 37, no. 6, pp. 1257–1269, 2011.
[16]
U. Meyer, E. Spoerri, B. K. Yee, M. J. Schwarz, and J. Feldon, “Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia,” Schizophrenia Bulletin, vol. 36, no. 3, pp. 607–623, 2010.
[17]
M. Nakazi, U. Bauer, T. Nickel, M. Kathmann, and E. Schlicker, “Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 361, no. 1, pp. 19–24, 2000.
[18]
N. Egashira, K. Mishima, S. Katsurabayashi et al., “Involvement of 5-hydroxytryptamine neuronal system in Δ9-tetrahydrocannabinol-induced impairment of spatial memory,” European Journal of Pharmacology, vol. 445, no. 3, pp. 221–229, 2002.
[19]
E. T. Tzavara, R. J. Davis, K. W. Perry et al., “The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions,” British Journal of Pharmacology, vol. 138, no. 4, pp. 544–553, 2003.
[20]
M. N. Hill, D. J. Froc, C. J. Fox, B. B. Gorzalka, and B. R. Christie, “Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo,” European Journal of Neuroscience, vol. 20, no. 3, pp. 859–863, 2004.
[21]
K. Zavitsanou, H. Wang, V. S. Dalton, and V. Nguyen, “Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats,” Neuroscience, vol. 169, no. 1, pp. 315–324, 2010.
[22]
S. L. Andersen, “Trajectories of brain development: point of vulnerability or window of opportunity?” Neuroscience and Biobehavioral Reviews, vol. 27, no. 1-2, pp. 3–18, 2003.
[23]
L. P. Spear, “The adolescent brain and age-related behavioral manifestations,” Neuroscience and Biobehavioral Reviews, vol. 24, no. 4, pp. 417–463, 2000.
[24]
Y. Watanabe, T. Someya, and H. Nawa, “Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models,” Psychiatry and Clinical Neurosciences, vol. 64, no. 3, pp. 217–230, 2010.
[25]
A. M. Samuelsson, E. Jennische, H. A. Hansson, and A. Holm?ng, “Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABAA dysregulation and impaired spatial learning,” American Journal of Physiology, vol. 290, no. 5, pp. R1345–R1356, 2006.
[26]
E. Scarr, G. Pavey, D. Copolov, and B. Dean, “Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects,” Schizophrenia Research, vol. 71, no. 2-3, pp. 383–392, 2004.
[27]
T. Ishibashi, T. Horisawa, K. Tokuda et al., “Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 171–181, 2010.
[28]
T. Ishiyama, K. Tokuda, T. Ishibashi, A. Ito, S. Toma, and Y. Ohno, “Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test,” European Journal of Pharmacology, vol. 572, no. 2-3, pp. 160–170, 2007.
[29]
M. Nakamura, M. Ogasa, J. Guarino et al., “Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 70, no. 6, pp. 829–836, 2009.
[30]
N. Müller and M. J. Schwarz, “The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression,” Molecular Psychiatry, vol. 12, no. 11, pp. 988–1000, 2007.
[31]
D. Moranta, S. Esteban, and J. A. García-Sevilla, “Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 5, pp. 516–524, 2004.
[32]
A. K. Walker, T. Nakamura, R. J. Byrne et al., “Neonatal lipopolysaccharide and adult stress exposure predisposes rats to anxiety-like behaviour and blunted corticosterone responses: implications for the double-hit hypothesis,” Psychoneuroendocrinology, vol. 34, no. 10, pp. 1515–1525, 2009.